Table 1 Patient demographics
From: Activity of PD1 inhibitor therapy in advanced sarcoma: a single-center retrospective analysis
N (%) | |
|---|---|
Age at time of diagnosis (years) | |
Younger than 50 | 21 (37.5%) |
50 or older | 35 (62.5%) |
Sex | |
Male | 33 (58.9%) |
Female | 23 (41.1%) |
Race/Ethnicity | |
White/Caucasian | 51 (91.1%) |
African American | 2 (3.6%) |
Latino/Hispanic | 2 (3.6%) |
Asian American | 1 (1.8%) |
Localized or metastatic (at time PD1i initiated) | |
Advanced, localized disease | 5 (8.9%) |
Metastatic disease | 51 (91.1%) |
Tumor pathology | |
Liposarcoma | 11 (19.6%) |
Leiomyosarcoma | 7 (12.5%) |
Synovial sarcoma | 4 (7.1%) |
Chordoma | 4 (7.1%) |
Spindle cell sarcoma | 4 (7.1%) |
Osteosarcoma | 3 (5.4%) |
Undifferentiated pleomorphic sarcoma | 3 (5.4%) |
Othera | 20 (35.7%) |
Primary site of tumor | |
Intra-abdominal | 15 (26.8%) |
Lower extremity | 13 (23.2%) |
Trunk | 11 (19.6%) |
Intra-thoracic | 4 (7.1%) |
Head/neck | 4 (7.1%) |
Uterus | 3 (5.4%) |
Upper extremity | 2 (3.6%) |
Other/unknown | 4 (7.1%) |
Immunotherapy drug(s) received | |
Nivolumab alone | 30 (53.6%) |
Pembrolizumab alone | 20 (35.7%) |
Nivolumab and ipilimumab combinationb | 6 (10.7%) |
Number of immunotherapy cycles received | |
Four or less cycles | 33 (58.9%) |
Greater than four cycles | 23 (41.1%) |
Other agent given with immunotherapy | |
Immunotherapy alone | 42 (75%) |
Immunotherapy with secondary agent | 14 (25%) |
# of prior therapies | |
Two or less | 29 (51.8%) |
More than two | 27 (48.2%) |
PD1 status | |
Positive | 17 (30.4%) |
Negative | 8 (14.3%) |
Unknown | 31 (55.4%) |
PDL1 status | |
Positive | 8 (14.3%) |
Negative | 18 (32.1%) |
Unknown | 30 (53.6%) |